Curis Lifesciences bulk deals
NSE: CURISPharmaceuticals & Biotechnology
Share price at the NSE close on 23 Oct 2026. Previous close ₹185.00.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price.
- ₹143 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 7 Jul 2026
- 20.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 7 Jul 2026
- 3.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonesince listing in Nov 2025
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record. The filing of 7 Jul 2026
- 14.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 7 Jul 2026
- 15.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 7 Jul 2026
- 0.46
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 4,000100.0% delivered
Curis Lifesciences bulk deals
Last 12 months, since 23 Oct 2025: 9 bulk deals, ₹6.40 Cr bought and ₹1.43 Cr sold Bought and sold in deals. Each deal's shares times its price, added up for the buyers and apart for the sellers, so a block deal, which names both, counts on each side.Today's bulk and block deals, all companies
ValueValue of a deal. The shares traded times the deal's price.Per cent of the companyPer cent of the company. The shares traded as a percentage of all the company's shares in issue on the day of the deal.
Friday 6 Mar 20262 firms · ₹0.88 Cr bought · ₹0.88 Cr soldNet nil
- BoughtSIXTH SENSE SECURITIES PRIVATE LIMITEDBought 93,000 at ₹95.141.15% of the company₹0.88 Cr
- SoldRS SECURITIESSold 93,000 at ₹95.051.15% of the company₹0.88 Cr
Monday 5 Jan 20262 firms · ₹0.83 Cr bought · ₹0.54 Cr soldNet bought ₹0.29 Cr
- BoughtSS CORPORATE SECURITIES LIMITEDBought 64,000 at ₹129.550.79% of the company₹0.83 Cr
- SoldVINEY GROWTH FUNDSold 42,000 at ₹129.150.52% of the company₹0.54 Cr
Friday 26 Dec 20251 firm · ₹0.71 Cr bought · ₹0 soldNet bought ₹0.71 Cr
- BoughtSS CORPORATE SECURITIES LIMITEDBought 61,000 at ₹116.540.75% of the company₹0.71 Cr
Friday 14 Nov 20254 firms · ₹3.97 Cr bought · ₹0 soldNet bought ₹3.97 Cr
- BoughtPREETI BHAUKABought 1,20,000 at ₹146.10₹1.75 Cr
- BoughtRADHU DEVELOPERS PRIVATE LIMITEDBought 53,000 at ₹143.00₹0.76 Cr
- BoughtJAIN SANJAY POPATLALBought 50,000 at ₹146.10₹0.73 Cr
- BoughtSACHIN KAPOORBought 50,000 at ₹146.10₹0.73 Cr
A bulk deal is one client trading half a per cent or more of the shares in a day; a block deal is a large trade in the exchange's separate block window, its buyer and its seller each on a line of their own. A firm that bought and sold the shares the same day is on one line, with its net. All 9 deals on record since listing on 14 Nov 2025.